 |
인쇄하기
취소
|
KFDA approves BMS' Baraclude, a B viral hepatitis therapy.
BMS Korea took a KFDA approval for B viral hepatitis drug called "Baraclude" (entecavir).
The mode of Baraclude's action is to reduce the viral infection to the host cells by blocking its proliferation of HBV (hepatitis B virus), which is indicated for the B hepatitis viral infected adults over 16 years old or more who are confirmed with active viral proliferation or sustained high level of ...
The mode of Baraclude's action is to reduce the viral infection to the host cells by blocking its proliferation of HBV (hepatitis B virus), which is indicated for the B hepatitis viral infected adults over 16 years old or more who are confirmed with active viral proliferation or sustained high level of ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.